arfarin is effectively used in a wide range of thromboembolic disorders for primary and secondary prevention. Patients on long-term therapy have a risk of 1%-3% per year for haemorrhage leading to hospitalisation or death.
1,2 Therefore, strategies to manage over-warfarinisation and warfarin during invasive procedures are important. 3, 4 Despite the associated bleeding risk, warfarin remains the most commonly prescribed anticoagulant in Australia and New Zealand. Common indications for the use of warfarin in the community include stroke prevention in atrial fibrillation (AF), preventing thrombus formation in patients with mechanical heart valves (MHV), and treatment of venous thromboembolism (VTE). For most warfarin indications, the target international normalised ratio (INR) is 2.0-3.0 (VTE and single MHV excluding mitral). For mechanical mitral valve or combined mitral and aortic valves, the target INR is 2.5-3.0. 5 New anticoagulants such as oral direct factor Xa inhibitors and direct thrombin inhibitors are becoming available as alternatives to warfarin. [6] [7] [8] However, it is likely that warfarin will continue to be widely used in the community among patients who are already stable on warfarin or have severe renal impairment (creatinine clearance, < 30 mL/ min), and for anticoagulation indications for which these novel agents have not been evaluated, such as MHV. 9, 10 This update of the previous consensus guidelines 11 is again on behalf of the Australasian Society of Thrombosis and Haemostasis (ASTH) and offers advice on strategies to prevent over-anticoagulation, the principles of warfarin reversal, and bridging anticoagulation therapy in different clinical settings. In particular, the focus is on managing:
• warfarin therapy complicated by bleeding;
• a supratherapeutic INR with no bleeding; and • warfarin therapy during invasive procedures.
The recommendations draw on available evidence and the clinical experience of the panel of author-practitioners.
Guideline development
As Australian and New Zealand-based experts in the field of thromboembolic disorders, we were invited to join the panel leading guideline development. The process included reviewing up-to-date evidence and existing highquality evidence-based international guidelines for warfarin reversal. We conducted a face-to-face meeting on 21 March 2011 at which specific questions and drafting of the guidelines were discussed. Further revisions were made by consensus via email. All six members of the panel are the authors of this article.
We based our recommendations on the body of evidence, with consideration of the strength of evidence, consistency across studies, likely clinical impact, and generalisability and applicability of study findings in the local setting.
An update of consensus guidelines for warfarin reversal
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Clinical focus
Guidelines
• Despite the associated bleeding risk, warfarin is the most commonly prescribed anticoagulant in Australia and New Zealand. Warfarin use will likely continue for anticoagulation indications for which novel agents have not been evaluated and among patients who are already stabilised on it or have severe renal impairment.
• Strategies to manage over-warfarinisation and warfarin during invasive procedures can reduce the risk of haemorrhage.
• For most warfarin indications, the target international normalised ratio (INR) is 2.0-3.0 (venous thromboembolism and single mechanical heart valve excluding mitral). For mechanical mitral valve or combined mitral and aortic valves, the target INR is 2.5-3.5.
• Risk factors for bleeding with warfarin use include increasing age, history of bleeding and specific comorbidities.
• For patients with elevated INR (4.5-10.0), no bleeding and no high risk of bleeding, withholding warfarin with careful subsequent monitoring seems safe.
• Vitamin K 1 can be given to reverse the anticoagulant effect of warfarin. When oral vitamin K 1 is used for this purpose, the injectable formulation, which can be given orally or intravenously, is preferred.
• For immediate reversal, prothrombin complex concentrates (PCC) are preferred over fresh frozen plasma (FFP). Prothrombinex-VF is the only PCC routinely used for warfarin reversal in Australia and New Zealand. It contains factors II, IX, X and low levels of factor VII. FFP is not routinely needed in combination with Prothrombinex-VF. FFP can be used when Prothrombinex-VF is unavailable. Vitamin K 1 is essential for sustaining the reversal achieved by PCC or FFP.
• Surgery can be conducted with minimal increased risk of bleeding if INR р 1.5. For minor procedures where bleeding risk is low, warfarin may not need to be interrupted. If necessary, warfarin can be withheld for 5 days before surgery, or intravenous vitamin K 1 can be given the night before surgery. Prothrombinex-VF use for warfarin reversal should be restricted to emergency settings. Perioperative management of anticoagulant therapy requires an evaluation of the risk of thrombosis if warfarin is temporarily stopped, relative to the risk of bleeding if it is continued or modified.
Relevant clinical questions guided systematic review of the evidence. We followed the GRADE (Grading of Recommendations Assessment, Development and Evaluation) method to generate recommendations. The strength of recommendations, designated strong (1) or weak (2) , is based on the quality of the body of evidence, which can be high (A), moderate (B) or low (C). 12 For recommendations where the quality of evidence was not sufficient to allocate a grade, the term "good practice point" (GPP) indicates the recommendation is based on the consensus opinion of the ASTH writing panel (Box 1). Consensus recommendations were reached in an equitable manner. Agreement of all members of the expert panel was required in order to proceed with making the recommendation.
Potential conflicts of interest were declared and recorded. Funding for this update was provided by a restricted educational grant from CSL Bioplasma that was administered by the ASTH.
Bleeding complications of warfarin therapy
Bleeding is the most common complication of warfarin therapy and is related to the INR value. Although incremental rises in INR increase the risk of bleeding, most intracranial bleeds are in patients with an INR in the therapeutic range; they occur in 0.5%-1.0% of patients with AF per year. 13, 14 Bleeding risk is also related to patient factors including age, a prior bleeding history and specific comorbidities. Elderly patients are generally more sensitive to warfarin and need a lower mean daily dose. 15, 16 Bleeding risk is greatest in the first 3 months after starting warfarin. An occurrence suggests an underlying organspecific lesion and should be appropriately investigated. 1, 17 Changes in concomitant medication potentially alter a patient's response to warfarin anticoagulation and increase their risk of bleeding. Drugs that commonly alter warfarin metabolism include antibiotics, amiodarone, statins, anticonvulsants and some herbal medications, such as St John's wort. Alcohol in small to moderate amounts probably has little effect on warfarin metabolism. Among heavy drinkers, however, associated factors such as increased falls, alcoholinduced gastritis, poor diet and poor compliance all increase the risk of bleeding. Bleeding prediction scores, such as HAS-BLED (hypertension, abnormal liver or renal function, stroke, bleeding history or predisposition, labile INR, elderly [> 65 years], alcohol or drugs concomitantly) for AF, may help to identify factors that can be modified to reduce the risk of warfarin-related bleeding but should not result in withholding of anticoagulation therapy. 18 General principles for preventing high INR include careful therapeutic monitoring and adopting other precautionary measures that can minimise bleeding risk due to high INR (Box 2).
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Warfarin reversal
Vitamin K 1 for reversal of warfarin-associated coagulopathy Vitamin K 1 is an effective antidote to the anticoagulant effect of warfarin. Despite this, data are lacking to show that its use improves outcome in life-threatening bleeds. Currently, phytomenadione is the only injectable formulation available in Australia and New Zealand. While intravenous or oral routes of administration can be used and are effective in reversing an INR that is raised because of warfarin therapy, the intravenous route achieves a more rapid response compared with oral administration, with an onset of action seen within 6-8 hours. However, both routes achieve a similar correction of INR by 24 hours. 23 Vitamin K 1 should not be administered by subcutaneous or intramuscular routes. Subcutaneous administration is no more effective than placebo, while intramuscular injection in an over-anticoagulated patient may lead to hae- matoma and bleeding, and its effect on reversal is unpredictable owing to variable absorption -it can be associated with a prolonged increase of vitamin K 1 plasma levels, which may hinder re-anticoagulation. 24, 25 The major concern about intravenous vitamin K 1 has been anaphylaxis. Although the absolute incidence is unknown, it is most likely rare. There is no convincing association between anaphylaxis and dose, concentration or rate of administration of vitamin K 1 but the literature suggests that current formulations with mixed micelles of lecithin and glycol are safer than the previous preparations containing polyethylated castor oil. 26 
Prothrombin complex concentrate and fresh frozen plasma
Replacement is necessary to correct the low levels of factors II, VII, IX and X induced by warfarin. This can be achieved by using a prothrombin complex concentrate (PCC) or fresh frozen plasma (FFP) (Box 3).
PCC are formulated with three factors (II, IX and X) or four factors (II, VII, IX and X). Advantages of PCC over FFP include rapid reconstitution into a small volume for infusion over 20-30 minutes, fast onset of action, no requirement to check a patient's blood group, minimal risk of viral transmission due to pathogen reduction and inactivation steps during manufacturing, 27 and reduced risk of other clinical adverse reactions such as transfusion-associated circulatory overload or transfusion-associated acute lung injury. The latter is due to circulating antihuman leukocyte antigen or antigranulocyte antibodies in plasma. 28, 29 However, PCC does contain small amounts of heparin and its use to reverse warfarin anticoagulation should be carefully considered in patients with heparin-induced thrombocytopenia. 27 Prothrombinex-VF, a three-factor PCC, is the only product currently in routine use in Australia and New Zealand for warfarin reversal. Due to its low levels of factor VII, the Warfarin Reversal Consensus Guidelines published in 2004 recommended that it be supplemented with FFP. 11 Since that time, there have been several reports of the successful use of a three-factor concentrate without addition of FFP. [30] [31] [32] [33] Prothrombinex-VF has been used successfully to electively reverse anticoagulation in patients on warfarin therapy with a stable INR, and achieved the target INR in over 90% of patients. 30 However, this study included few patients (14%) with INR > 3.5 requiring normalisation of the INR. Patients with major or life-threatening bleeding or INR > 10.0 accompanied by high risk of bleeding are of great concern to clinicians, and the efficacy of Prothrombinex-VF when used alone in these patients has not been extensively evaluated. In such patients, supplementing factor VII by administering FFP should ensure optimal reversal of the anticoagulant effect of warfarin.
The previous Warfarin Reversal Consensus Guidelines recommended three-factor PCC (Prothrombinex-HT) be administered at a dose range of 25-50 IU/kg. 11 The revised dosing recommendations for various clinical scenarios included in this update are based on panel consensus alone (ie, rather than gradable evidence). The suggested dose of Prothrombinex-VF for reversal of the anticoagulant effect of warfarin is based on initial and target INRs (Box 4). 30 Prothrombinex-VF is able to completely reverse an excessive INR within 15 minutes, but the infused clotting factors have half-lives similar to endogenous clotting factors. Therefore, vitamin K 1 5-10 mg should be given intravenously with the PCC to sustain the reversal effect. Heparin-induced thrombocytopenia * CSL Bioplasma. † For more comprehensive information on these products, refer to approved product information 27 and blood service data. 28, 29 ‡ Thrombotic complications of prothrombin complex concentrates appear to be rare. Since 1993 thrombotic episodes with Prothrombinex-VF or its predecessor, Prothrombinex-HT, have been rarely reported to CSL Bioplasma. 27, 28 ◆ FFP contains all coagulation factors present in whole blood but it is not a factor concentrate, and multiple units may be needed if FFP alone is used for warfarin reversal. In addition to the inherent risks of plasma use mentioned already, requirements for its use include the need to determine the patient's blood group (or to use group AB plasma), appropriate facilities for frozen plasma storage and thawing, and the time taken for infusion. Therefore, FFP should not be used routinely to reverse warfarin anticoagulation; however, where PCC is unavailable and emergency reversal is required, FFP should be used, along with vitamin K 1 to sustain the reversal effect.
Treating a patient with bleeding, regardless of INR
For patients on warfarin therapy with bleeding in whom the aim is to normalise the INR, vitamin K 1 given intravenously is the preferred treatment because of its faster and predictable onset of action. For this indication, doses р 3 mg are ineffective. Consistent with other guidelines, we recommend a dose of 5-10 mg. 25, 34, 35 Our recommendations for managing patients on warfarin therapy with bleeding are summarised in Box 5. For life-threatening (critical organ) and clinically significant bleeds, the consensus is to use the maximum dose of Prothrombinex-VF (with vitamin K 1 and FFP) and the maximum amount of FFP when Prothrombinex-VF is unavailable.
Treating patients with high INR and no bleeding
Among patients with an elevated INR up to 10.0 who do not have bleeding or risk factors for major bleeding, it has been shown that oral administration of low-dose vitamin K 1 does not lower the risk of bleeding compared with placebo and should not be used routinely. 36 However, for patients with risk factors for bleeding, vitamin K 1 1-2 mg orally or 0.5-1.0 mg intravenously should be considered. Risk factors for major bleeding include a major bleed within the previous 4 weeks, surgery within the previous 2 weeks, a platelet count less than 50 10 9 /L, known liver disease or concurrent antiplatelet therapy. There are no randomised studies to guide management of patients whose INR exceeds 10.0 and who are not bleeding. A recent single-arm study involving outpatients with an INR greater than 10.0 reported a low rate of major bleeding when these patients received 2.5 mg of oral vitamin K 1 . 37 Our recommendations for managing patients with high INR and no bleeding are summarised in Box 6. Many patients on warfarin are outpatients and information on individual patient bleeding risk is frequently not available to laboratory staff who are involved in reporting elevated INR results and attempting to communicate results to patients. In these settings, good communication between clinical and laboratory staff is essential. • Recommence warfarin on the night of surgery at the previous maintenance dose (2C)
• Patients at high risk for arterial and venous thromboembolism should be considered for bridging anticoagulation with therapeutic low molecular weight heparin (LMWH) or an infusion of unfractionated heparin. 39 Bridging may include a heparin before and/or after surgery. It should be noted that quality evidence is lacking to show that bridging with heparin reduces arterial thromboembolism in patients with AF but is associated with increased bleeding (see below). Bridging is usually not needed in patients with low-risk AF (CHADS 2 score 0-2 and no history of TIA or stroke), or VTE occurring more than 3 months before surgery.
Bridging with a heparin is associated with an added risk of surgical bleeding that varies depending on the type of surgery (20% with major surgery, compared with 0.7% with minor surgery). 40 The risk of bleeding should be considered in the context of the severe consequences of thromboembolic stroke (death in 40% and severe disability in 30% of patients).
Traditionally, warfarin has been stopped 5 days before a major operation. Surgery can proceed safely if the INR is < 1.5 on the day of surgery. To avoid cancellations because the INR is above this level, the INR can be checked on the day before surgery and vitamin K 1 can be administered if needed. In patients who are given heparin before surgery, an LMWH is usually started when the INR is < 2.0 (typically on the third morning after the last warfarin dose) and continued until 24 hours before surgery; some guidelines recommend halving the last dose of LMWH before surgical procedures associated with a high bleeding risk. 41 The above method can be labour intensive. In patients with a stable INR of 2.0-3.0 during the preceding 4 weeks, vitamin K 1 3 mg given intravenously on the evening (12-18 hours) before surgery has been shown to be effective in achieving a preoperative INR of < 1.5 in 94%, with few episodes of major bleeding related to surgery and low rates of warfarin resistance when restarting the drug. 42 Both methods using vitamin K 1 to reverse warfarin anticoagulation often require hospital in the home services or a general practitioner to administer the subcutaneous LMWH or intravenous vitamin K 1 , and can result in higher rates of cancellation of surgery if the INR is > 1.5 on the day of surgery.
For patients who need urgent surgery while receiving warfarin therapy, three-factor PCC can effectively reverse the anticoagulant effect.
30,31 PCC should not be used routinely to enable elective surgery however, as vitamin K 1 is effective and less costly.
Many dental, dermatological or ophthalmological procedures are associated with a low bleeding risk. Patients with a low bleeding risk need not stop warfarin.
Bleeding risk can be minimised after major surgery by adjusting the time when anticoagulant is resumed, according to the anticipated surgical bleeding risk and the extent of intraoperative or immediate postoperative bleeding. This means that therapeutic LMWH is delayed for 48-72 hours or substituted with prophylactic LMWH in patients having major surgery with a high bleeding risk. 43 Bleeding risk is low after minor procedures if therapeutic LMWH is started about 24 hours after surgery. Warfarin can be restarted on the evening of surgery at the previous maintenance dose if there is adequate surgical haemostasis.
The strategies that can be used to manage patients on long-term warfarin therapy during surgery and other invasive procedures are summarised in Box 8. These strategies are not associated with a delay in re-establishing a therapeutic INR when resuming warfarin after surgery.
